The direct detection of pyrazinamide resistance in Mycobacterium tuberculosis is sufficiently difficult that many laboratories do not attempt it. Most pyrazinamide resistance is caused by mutations that inactivate the pyrazinamidase enzyme needed to convert the prodrug pyrazinamide to its active form. We evaluated two newer and simpler methods to assess pyrazinamidase activity, the nitrate redu...

The effects of administration of drug combinations on uric acid excretion were studied in order to test the hypothesis that a portion of renal tubular reabsorption of uric acid occurs distal to the uric acid secretory site. Oral administration of pyrazinamide (3 g) during probenecid uricosuria (probenecid 500 mg every 6 h) decreased urate excretion from 463 mug/min following probenecid medicati...

Khuhawar et al. (1998) studied the HPLC determination of rifampicin, isoniazid and pyrazinamide in the pharmaceutical preparations. Isoniazid alone and along with pyrazinamide and rifampicin has been estimated by HPLC. Rifampicin and pyrazinamide were separated from the derivative of isoniazid and are simultaneously determined. The chromatography is carried out from C18 column. These drugs were...

The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. ...

OBJECTIVES To investigate the presence of mutations in the pncA gene in 31 pyrazinamide-resistant Mycobacterium tuberculosis and 5 susceptible strains. MICs and pyrazinamidase (PZase) activity were also determined. METHODS All 36 M. tuberculosis clinical isolates were genotyped by mycobacterial interspersed repetitive units (MIRUs) and most were also typed by spoligotyping. The MIC value nece...

OBJECTIVES Pyrazinamide is a key first-line tuberculosis drug. Reliable drug susceptibility testing (DST) data are of clinical importance, but in vitro testing is challenging since the activity of pyrazinamide is pH sensitive. The BACTEC MGIT 960 is considered the principal reference technique, but Wayne's test is an alternative, although it may be difficult to interpret. A further alternative ...

Abstract Pyrazinamide (PZA), a medication for tuberculosis, has high aqueous solubility and low permeability, undergoes extensive liver metabolism, exhibits toxicity through its metabolites. To avoid this, PZA in lipid core-shell nanoarchitectonics been formulated to target lymphatic uptake provide metabolic stability the incorporated drug. The UPLC-MS/MS method reliable vitro quantitative anal...

In 1952 the clinical use of pyrazinamide (PZA) was first reported by Yeager, Munroe, and Dessa&. In 1954 McCune, Tompsett, and McDermott2 observed that the combined use of isoniazid and pyrazinamide in the treatment of pulmonary tuberculosis was especially effective. Isoniazid (INH) and pyrazinamide have been employed at the San Fernando Veterans Administration Hospital since 1952, but not unti...